 |
 |
South Staffordshire Joint Formulary
Cannock Chase Clinical Commissioning Group
East Staffordshire Clinical Commissioning Group
South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group
Stafford and Surrounds Clinical Commissioning Group |
| Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
|
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
08.01 |
Cytotoxic drugs
(2,0)
|
|
08.01.01 |
Alkylating drugs
(4,7)
|
|
08.01.02 |
Anthracyclines and other cytotoxic antibiotics
(1,13)
|
|
08.01.03 |
Antimetabolites
(9,12)
|
|
08.01.04 |
Vinca alkaloids and etoposide
(1,9)
|
|
08.01.05 |
Other antineoplastic drugs
(34,0)
|
|
|
Arsenic trioxide
(1,0)
|
|
|
Bevacizumab
(1,0)
|
|
|
Brentuximab vedotin
(1,0)
|
|
|
Dacarbazine and Temozolomide
(1,1)
|
|
|
Hydroxycarbamide
(1,0)
|
|
|
Ipilimumab
(1,0)
|
|
|
Protein kinase inhibitors
(22,3)
|
|
|
Taxanes
(4,0)
|
|
|
Topoisomerase I inhibitors
(2,0)
|
|
|
Trabectedin
(1,0)
|
|
|
Trastuzumab
(2,0)
|
|
08.02 |
Drugs affecting the immune response
(0,0)
|
|
08.02.01 |
Antiproliferative immunosuppressants
(2,2)
|
|
08.02.02 |
Corticosteroids and other immunosuppressants
(5,11)
|
|
08.02.03 |
Anti-lymphocyte monoclonal antibodies
(16,0)
|
|
08.02.04 |
Other immunomodulating drugs
(8,2)
|
|
|
Interferon Alfa
(3,2)
|
|
|
Interferon beta
(1,0)
|
|
|
Dimethyl fumarate
(1,0)
|
|
|
Fingolimod
(1,0)
|
|
|
Glatiramer acetate
(1,0)
|
|
|
Lenalidomide, pomalidomide, and thalidomide
(2,0)
|
|
|
Mifamurtide
(1,0)
|
|
|
Natalizumab
(1,0)
|
|
08.03 |
Sex hormones and hormone antagonists in malignant disease
(0,0)
|
|
08.03.01 |
Oestrogens
(2,1)
|
|
08.03.02 |
Progestogens
(0,4)
|
|
08.03.03 |
Androgens
(0,0)
|
|
08.03.04 |
Hormone antagonists
(0,0)
|
|
08.03.04.01 |
Breast cancer
(5,5)
|
|
08.03.04.02 |
Prostate cancer and gonadorelin analogues
(0,0)
|
|
|
Gonadorelin analogues
(1,1)
|
|
|
Anti-androgens
(10,4)
|
|
08.03.04.03 |
Somatostatin analogues
(3,0)
|
|
|
|
